Case Report: Telitacicept for interstitial lung disease associated with idiopathic inflammatory myopathies: an observational study
Telitacicept demonstrates substantial clinical efficacy in the treatment of IIM-associated ILD, accompanied by a low infection rate and a favorable safety profile.
Authors
- Huanzi Dai (ORCID: https://orcid.org/0000-0002-7493-7272)
- Xingjuan Xie (ORCID: https://orcid.org/0000-0002-3789-9182)
- Chen Xue (ORCID: https://orcid.org/0000-0003-4062-9009)
- Mengshan Li (ORCID: https://orcid.org/0000-0003-3254-3467)
- Yan Chen (ORCID: https://orcid.org/0000-0002-5260-7301)
- Mingfang Sun (ORCID: https://orcid.org/0000-0003-0194-4903)
- Xi Zhao (ORCID: https://orcid.org/0009-0008-8215-0243)
Institutions
- Army Medical University (CN)
- Daping Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.3389/fphar.2025.1647543
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centre Scientifique et Technique du Bâtiment